Assess whether to drop a secondary endpoint that will dominate the AdCom

SITUATION A CMO 483 that maps to the NDA CMC module put scientific-advice briefing book in front of clinical-development physician in a 505(b)(2) program relying on literature plus a bridging study. This Pharma & Life Sciences / Pharmacovigilance close is to drop a secondary from scientific-advice briefing book, and the live options are Proceed under protocol, Pause the pathway, Escalate safety review.

DECISION Clinical-development physician in a 505(b)(2) program relying on literature plus a bridging study must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using scientific-advice briefing book after a CMO 483 that maps to the NDA CMC module.

HYPOTHESES TO TEST 1. Scientific-advice briefing book reads as Proceed under protocol once a CMO 483 that maps to the NDA CMC module is lined up to the same Pharma & Life Sciences population. 2. Scientific-advice briefing book is closer to Pause the pathway after a CMO 483 that maps to the NDA CMC module; Proceed under protocol would over-claim this Pharmacovigilance extract. 3. Escalate safety review is still live in scientific-advice briefing book for clinical-development physician in a 505(b)(2) program relying on literature plus a bridging study. 4. Scientific-advice briefing book is missing the fact clinical-development physician needs after a CMO 483 that maps to the NDA CMC module; stop this Pharma & Life Sciences close.

ANALYSIS REQUIRED 1. Trace CMC, labeling, or pharmacovigilance facts in scientific-advice briefing book after a CMO 483 that maps to the NDA CMC module. 2. Separate an isolated adverse event from a systemic quality issue. 3. Test a protocol deviation versus a safety signal versus a filing gap on to drop a secondary. 4. For this Pharma & Life Sciences Pharmacovigilance file, read scientific-advice briefing book against a CMO 483 that maps to the NDA CMC module and write the one fact that would move to drop a secondary for clinical-development physician.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / Pharmacovigilance packet (scientific-advice briefing book after a CMO 483 that maps to the NDA CMC module). The follow-on Pharmacovigilance action is what clinical-development physician does next: implement the option, assign an owner, and log the missing fact.

COMMAND RETURNS - Bottom-line Pharma & Life Sciences option on to drop a secondary, then the evidence in scientific-advice briefing book, then the action for clinical-development physician - Hypothesis scorecard against scientific-advice briefing book: supported / rejected / untestable - Regulatory or exam hook Pharmacovigilance would cite - Pharmacovigilance finding in scientific-advice briefing book that a second reviewer can re-perform